NDA 220860 · Takeda Pharms USA
Orzeyful
Oveporexton · Oral
NovelPriority reviewOrphanCDER novel approval, Aug 5, 2026: To treat narcolepsy type 1
Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Aug 5, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2
2 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 10, 2026.
ORZEYFUL TM is indicated for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adult patients. ORZEYFUL is an orexin receptor 2 (OX2R) agonist indicated for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adult patients. ( 1 )
Mechanism: The mechanism of action of oveporexton in the treatment of narcolepsy type 1 (NT1) is through agonism of the orexin receptor 2 (OX2R). NT1 is associated with the loss of orexin neuropeptide signaling.
Therapeutic areas: Neurology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 5, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
3 products under this application
- ORZEYFUL · OVEPOREXTON 2MG · TABLET, ORAL · Prescription
- ORZEYFUL · OVEPOREXTON .05MG · TABLET, ORAL · Prescription
- ORZEYFUL · OVEPOREXTON 1MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Oveporexton" as an intervention, any sponsor and status, largest first.
- A Study of TAK-861 for the Treatment of Narcolepsy Type 1Pivotal-lookingCompleted
TakedaTakeda (TAK)
NCT06470828 · 168 participants · Start Jul 2, 2024 · Primary completion Jun 3, 2025
Drug: Oveporexton; Placebo · For: Narcolepsy Type 1
Sites: Phoenix, Arizona; Redwood City, California; Santa Ana, California · 53 sites in all
- A Study of TAK-861 in People With Narcolepsy Type 1Pivotal-lookingCompleted
TakedaTakeda (TAK)
NCT06505031 · 105 participants · Start Oct 8, 2024 · Primary completion Jun 4, 2025
Drug: TAK-861; Placebo · For: Narcolepsy Type 1
Sites: Glebe, Australia; Linz, Austria; Alken, Belgium · 28 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Oveporexton, an Oral Orexin Receptor 2-Selective Agonist, in Narcolepsy Type 1.
Dauvilliers Y, Plazzi G, Mignot E, et al. · N Engl J Med 2025 · Clinical Trial, Phase II, Randomized Controlled Trial
- Oveporexton for Narcolepsy Type 1 - Results from Two Phase 3 Trials.
Dauvilliers Y, Mignot E, Antczak J, et al. · N Engl J Med 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- Defining a Clinically Meaningful Within-Person Change Threshold for the Psychomotor Vigilance Test in Narcolepsy Type 1.
Harel BT, Pietrzak RH, Dave S, et al. · Ther Innov Regul Sci 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Effects of Oveporexton, an Orexin Receptor 2-Selective Agonist, on Cognition in Narcolepsy Type 1: A Secondary Analysis of a Randomized Clinical Trial.
Lammers GJ, Plazzi G, Mignot E, et al. · JAMA Neurol 2026 · Randomized Controlled Trial, Clinical Trial, Phase II
- Efficacy and safety of selective orexin 2 receptor agonists in narcolepsy type 1: a systematic review and meta-analysis of randomized controlled trials.
Yuan L, Huang YB, Chen YX, et al. · J Neurol 2026 · Systematic Review, Meta-Analysis
- Short-Term Efficacy and Safety of Oral Selective Orexin-2 Receptor Agonists in Narcolepsy Type 1: An Updated Systematic Review and Meta-Analysis of Randomized Trials.
Ali A, Sajjad A, Talha M, et al. · Neuropsychopharmacol Rep 2026 · Meta-Analysis, Systematic Review
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.